Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of generic galantamine 8 mg capsule vs reference in healthy Thai volunteers under fasting and fed conditions
TCTR20241215009Phase 1Not yet recruiting
- Sponsor
- Unison Laboratories
- Start
- Mar 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of galantamine in Alzheimer's disease (AD) (2 arms), sponsored by Unison Laboratories. Primary endpoint: Primary pharmacokinetic bioequivalence endpoints. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
galantamine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on TCTR20241215009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20241215009.